thirty-nine patients with metastatic breast cancer who had not received prior chemotherapy for metastatic disease were treated in a phase ii trial with a combination of mitoxantrone ( 10 mg/m2 ) , methotrexate ( 40 mg/m2 ) and 5-fluorouracil ( 600 mg/m2 ) i.v . every 3 weeks ( mmf ) .
C0025677
methotrexate
C0083765
mmf